What is the recommended course of action for an older patient with a history of cancer, who has undergone an MRI examination of the brain revealing multiple metastatic lesions, a recent infarct, and small vessel disease?

MRI Brain Report Interpretation and Management

Critical Findings Summary

This MRI reveals multiple brain metastases (largest 2.5 cm in left cerebellum), an acute right frontal infarct, and chronic small vessel disease in an older cancer patient—requiring urgent multidisciplinary neurosurgical, neuro-oncology, and stroke neurology evaluation within 24-48 hours. 1, 2

---

Immediate Clinical Priorities

1. Emergency Assessment for Cerebellar Metastasis

The 2.5 cm left cerebellar lesion is particularly concerning and requires urgent evaluation for:

• Obstructive hydrocephalus: The cerebellar location can block CSF flow through the fourth ventricle, causing acute neurological deterioration—this is a neurosurgical emergency 2
• Mass effect on brainstem: Direct compression can cause rapid clinical decline 2
• Hemorrhage risk: The restricted diffusion pattern raises concern for hemorrhagic transformation, especially common in lung cancer and melanoma metastases 2, 3

Immediate action: Assess for signs of increased intracranial pressure (headache, nausea, altered consciousness, gait instability) and obtain emergent neurosurgical consultation if symptomatic 2

2. Corticosteroid Management

• Start dexamethasone 16 mg/day in divided doses (e.g., 4 mg four times daily with breakfast, lunch, dinner, and bedtime) given the multiple lesions with perifocal edema and symptomatic presentation 1, 2
• For asymptomatic or mildly symptomatic patients, 4-8 mg/day may suffice, but the presence of a large cerebellar lesion with edema warrants higher dosing 1
• Taper as quickly as clinically feasible (ideally within 3 weeks) to avoid toxicity including personality changes, immunosuppression, metabolic derangements, insomnia, and impaired wound healing 1, 2

---

Diagnostic Interpretation

Multiple Brain Metastases

The imaging characteristics strongly support metastatic disease:

• Location: Scattered at gray-white junction in both cerebral and cerebellar hemispheres—classic distribution for hematogenous spread 1
• Signal characteristics: Hypo/isointense T1, hyperintense T2/FLAIR with restricted diffusion and faint rim enhancement—consistent with hypercellular metastases 1
• Perifocal edema: Vasogenic edema pattern typical of metastases 1

Differential diagnosis considerations: While metastases are most likely given cancer history, the restricted diffusion pattern could also suggest:

• Abscesses (but these typically have central restricted diffusion in necrotic core, not just peripheral) 1
• CNS lymphoma (less likely with rim enhancement pattern) 1
• Multiple embolic infarcts (but these lack the nodular enhancement and have wedge-like shapes) 1

Right Frontal Cortical Infarct

The acute infarct shows:

• Low T1, high T2/FLAIR signal with restricted diffusion
• No contrast enhancement (typical for acute phase; enhancement develops in subacute phase days to weeks later) 1
• Wedge-like cortical distribution distinguishes this from metastasis 1

Clinical significance: This represents a separate acute vascular event, possibly related to:

• Hypercoagulable state from malignancy
• Tumor emboli (though imaging suggests bland infarct)
• Underlying small vessel disease (see below)

Chronic Small Vessel Disease

The bilateral periventricular white matter changes and lacunar infarcts represent chronic arteriolosclerotic leukoencephalopathy:

• Age-related microvascular changes 4, 5
• Interestingly, research suggests small vessel disease may be protective against brain metastases (OR 0.31), possibly due to altered vascular permeability 6
• However, this increases stroke risk and contributes to cognitive decline 4, 5

---

Systemic Staging Workup

Identify Primary Cancer Source

If primary cancer is unknown or incompletely staged:

• CT chest and abdomen with contrast or FDG-PET/CT to identify primary tumor and assess systemic disease burden 1, 7
• Laboratory tests: CBC, comprehensive metabolic panel, LDH (prognostic value in stage IV disease) 7
• Tissue diagnosis: If no known primary, biopsy of most accessible lesion (systemic site preferred over brain) to guide targeted therapy 7

Molecular Testing (Critical for Lung Cancer)

If lung cancer is the primary:

• EGFR mutation testing: CNS-penetrant TKIs (osimertinib) may control brain disease and delay need for radiation 2
• ALK rearrangement: Next-generation ALK inhibitors show significant CNS activity 2
• PD-L1 expression: Guides immunotherapy eligibility 2

Rationale: 44-60% of patients with druggable oncogene drivers develop brain metastases, and CNS-penetrant targeted therapy may be superior to upfront radiation in selected cases 2

---

Treatment Strategy Based on Disease Burden

For Multiple (>3) Brain Metastases

This patient has "diffuse multifocal disease" (4-8 lesions constitute this category) 1:

Primary treatment options:

1. Whole-brain radiation therapy (WBRT): Standard dosing is 30 Gy in 10 fractions or 37.5 Gy in 15 fractions 1

   • For poor neurologic performance: 20 Gy in 5 fractions 1

2. Stereotactic radiosurgery (SRS): May be considered if good performance status and low total tumor volume, despite multiple lesions 1

3. Systemic therapy first: If neurologically asymptomatic and druggable molecular target identified (e.g., EGFR-mutant NSCLC), CNS-penetrant targeted therapy before radiation is reasonable 1, 2

Special consideration for cerebellar lesion: The large symptomatic cerebellar metastasis may require:

• Surgical resection if causing mass effect, hydrocephalus, or hemorrhage 1, 2
• Urgent decompression if neurologically unstable 2
• Followed by adjuvant radiation (SRS to resection cavity or WBRT) 1

---

Follow-Up Imaging Schedule

After Initial Treatment

• Brain MRI every 2-3 months for first 1-2 years, then as clinically indicated 1
• Earlier scans if new/worsening symptoms or history of rapid progression 1
• Use 3D T1-weighted post-contrast sequences for early assessment of systemic therapy efficacy (within weeks of new regimen) 1

Monitoring Challenges

• Radiation necrosis vs. tumor progression: Can be difficult to distinguish after SRS; may require advanced imaging (perfusion MRI, amino acid PET) or tissue sampling 1
• Pseudoprogression: Enhancement may increase initially with immunotherapy before improving 1

---

Prognostic Considerations

RTOG Recursive Partitioning Analysis (RPA) Classification

Prognosis depends on:

• RPA Class I (median survival 7.1 months): KPS ≥70%, age <65, controlled systemic disease, brain-only metastases 1
• RPA Class II (median survival 4.2 months): KPS ≥70% but age ≥65 OR uncontrolled systemic disease OR extracranial metastases 1
• RPA Class III (median survival 2.3 months): KPS <70% 1

This patient's factors:

• Older age (unfavorable)
• Multiple brain metastases (unfavorable)
• Acute stroke complication (unfavorable)
• Unknown systemic disease status (needs assessment)

---

Critical Pitfalls to Avoid

1. Delaying neurosurgical evaluation: Cerebellar lesions can cause rapid deterioration from hydrocephalus—maintain low threshold for urgent consultation 2

2. Overlooking stroke management: The acute right frontal infarct requires standard stroke care (antiplatelet therapy, risk factor modification) in addition to cancer treatment 1

3. Prolonged high-dose steroids: Taper dexamethasone aggressively once clinically stable to minimize toxicity 1, 2

4. Missing molecular testing: Failure to test for actionable mutations (EGFR, ALK) may deny patients CNS-penetrant targeted therapies that could delay or avoid radiation 2

5. Assuming all enhancing lesions are metastases: The differential includes infection, inflammatory disease, and radiation necrosis (if prior treatment)—consider biopsy if atypical features 1, 7